Revance Therapeutics (RVNC) Tops Q3 EPS by 25c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.64), $0.25 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• J.Jill Inc. (JILL) PT Raised to $25 at BTIG